GSK’s Withdrawn Blood Cancer Drug Paves Path Back to Market
3 days ago · Blenrep has been removed from the drugmaker’s own financial outlook, however GSK sees potential peak annual sales of over £3 billion ($3.8 billion) if the treatment is approved. The results and the safety data will be presented at a December scientific meeting, GSK said. (Updates with details from press call from second paragraph) GSK Plc ...
GSK Raises Prospects For Withdrawn Blood Cancer Drug Blenrep …
2 days ago · On Thursday, GSK plc (NYSE:GSK) released headline results from a planned interim analysis of the DREAMM-7 head-to-head phase 3 trial of Blenrep (belantamab mafodotin) in combination with ...
Press release archive - GSK
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category. Press releases issued by our local operating companies can be viewed on our market websites.
GSK reports positive outcomes from Phase III multiple myeloma …
1 day ago · GSK has announced positive headline interim analysis outcomes from a Phase III trial, which is evaluating Blenrep (belantamab mafodotin) along with bortezomib and dexamethasone (BorDex) for ...
Blenrep shows overall survival benefit in head-to-head DREAMM-7 ... - GSK
3 days ago · Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “The overall survival results from the DREAMM-7 trial underscore the potential for this Blenrep combination to extend the lives of patients with relapsed/refractory multiple myeloma. This is a statistically significant and clinically meaningful advancement for ...
GSK announces Blenrep met key secondary endpoint in DREAMM …
3 days ago · GSK announced positive headline results from a planned interim analysis of the DREAMM-7 head-to-head phase III trial evaluating Blenrep in combination with bortezomib plus dexamethasone as a ...
GSK Steps Up Parkinson’s Focus With US Biotech Deal
4 days ago · Listen. 1:49. GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug development for Parkinson’s disease. GSK will pay $80 ...
GSK invests up to $800 million in Pennsylvania site, largest ...
Oct 24, 2024 · The up to $800 million investment will bring state-of-the-art drug substance manufacturing and additional drug product manufacturing capabilities to the company’s site in Marietta, Pennsylvania, along with over 200 new jobs.
Press releases | GSK US
US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit.
GSK to Pay Over $2 Billion in Bid to End Most U.S. Zantac Lawsuits ...
Oct 9, 2024 · GSK agreed to pay more than $2 billion to settle almost all remaining liability cases in the U.S. over allegations its discontinued heartburn medicine Zantac causes cancer.